Skip to content

Advertisement

Open Access

Erratum to: Validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria

  • Bernhard Rintelen1, 2Email author,
  • Jochen Zwerina3,
  • Manfred Herold4,
  • Franz Singer5,
  • Johann Hitzelhammer6,
  • Wolfgang Halder7,
  • Gabriela Eichbauer-Sturm8,
  • Rudolf Puchner9,
  • Miriam Stetter10,
  • Burkhard F. Leeb1, 2, 11 and
  • on behalf of the BIOREG investigator group
BMC Musculoskeletal DisordersBMC series – open, inclusive and trusted201617:412

https://doi.org/10.1186/s12891-016-1270-x

Published: 3 October 2016

The original article was published in BMC Musculoskeletal Disorders 2016 17:358

Erratum

After publication of the original article [1], it came to the authors’ attention that in the third paragraph of the ‘Discussion’ section, the value of DAS28 in NEW included patients is indicated wrongly, although correctly cited in Table 2. The correct form of the erroneous sentence is as follows:

“NEW patients´ median disease activity according to the DAS28 before starting bDMARDs is in the lower range in BIOREG compared to other European bDMARD registries (4.46 compared to 4.2–6.6), while median HAQ-DI scores are in a comparable range (1.0 vs 0.8–1.9).”

To correct the original sentence, “(4.46 compared to 4.2–6.6)” should be updated to “(4.13 compared to 4.2–6.6)”, and “in the lower range” should replace “somewhat lower”.

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Lower Austrian State Hospital Stockerau, 2nd Department for internal medicine, Lower Austrian Center for Rheumatology, Stockerau, Austria
(2)
Karl Landsteiner Institute for Clinical Rheumatology, Stockerau, Austria
(3)
Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling, 1st Medical Department, Hanusch Hospital Vienna, Vienna, Austria
(4)
Medical University of Innsbruck, Innsbruck, Austria
(5)
BIOREG, Vienna, Austria
(6)
Health Center Vienna Mariahilf, Wiener Gebietskrankenkasse, Vienna, Austria
(7)
Tyrolean State Hospital Hochzirl, Hochzirl, Austria
(8)
Office based rheumatologist, Linz, Austria
(9)
Office based rheumatologist, Wels, Austria
(10)
Department for Internal Medicine, Lower Austrian State Hospital Amstetten, Amstetten, Austria
(11)
Medical University of Graz, Graz, Austria

References

  1. Rintelen B, Zwerina J, Herold M, Singer F, Hitzelhammer J, Halder W, et al. Validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria. BMC Musculoskelet Disord. 2016;17:358. doi:10.1186/s12891-016-1207-4.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2016

Advertisement